Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Silvia Monestiroli is active.

Publication


Featured researches published by Silvia Monestiroli.


Nature Medicine | 2005

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Vania Gelmetti; Francesco Marchesi; Andrea Viale; Lucia Altucci; Clara Nervi; Saverio Minucci; Pier Giuseppe Pelicci

Histone deacetylases (HDACs) regulate transcription and specific cellular functions, such as tumor suppression by p53, and are frequently altered in cancer. Inhibitors of HDACs (HDACIs) possess antitumor activity and are well tolerated, supporting the idea that their use might develop as a specific strategy for cancer treatment. The molecular basis for their selective antitumor activity is, however, unknown. We investigated the effects of HDACIs on leukemias expressing the PML-RAR or AML1-ETO oncoproteins, known to initiate leukemogenesis through deregulation of HDACs. Here we report that: (i) HDACIs induce apoptosis of leukemic blasts, although oncogene expression is not sufficient to confer HDACI sensitivity to normal cells; (ii) apoptosis is p53 independent and depends, both in vitro and in vivo, upon activation of the death receptor pathway (TRAIL and Fas signaling pathways); (iii) TRAIL, DR5, FasL and Fas are upregulated by HDACIs in the leukemic cells, but not in normal hematopoietic progenitors. These results show that sensitivity to HDACIs in leukemias is a property of the fully transformed phenotype and depends on activation of a specific death pathway.


Nature | 2009

Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells.

Andrea Viale; Francesca De Franco; Annette Orleth; Valeria Cambiaghi; Virginia Giuliani; Daniela Bossi; Chiara Ronchini; Simona Ronzoni; Ivan Muradore; Silvia Monestiroli; Alberto Gobbi; Myriam Alcalay; Saverio Minucci; Pier Giuseppe Pelicci

Rare cells with the properties of stem cells are integral to the development and perpetuation of leukaemias. A defining characteristic of stem cells is their capacity to self-renew, which is markedly extended in leukaemia stem cells. The underlying molecular mechanisms, however, are largely unknown. Here we demonstrate that expression of the cell-cycle inhibitor p21 is indispensable for maintaining self-renewal of leukaemia stem cells. Expression of leukaemia-associated oncogenes in mouse haematopoietic stem cells (HSCs) induces DNA damage and activates a p21-dependent cellular response, which leads to reversible cell-cycle arrest and DNA repair. Activated p21 is critical in preventing excess DNA-damage accumulation and functional exhaustion of leukaemic stem cells. These data unravel the oncogenic potential of p21 and suggest that inhibition of DNA repair mechanisms might function as potent strategy for the eradication of the slowly proliferating leukaemia stem cells.


The EMBO Journal | 2004

Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.

Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Roberta Carbone; Mark Pearson; Giancarlo Pruneri; Giuseppe Viale; Ettore Appella; Pier Giuseppe Pelicci; Saverio Minucci

Mutations of p53 are remarkably rare in acute promyelocytic leukemias (APLs). Here, we demonstrate that the APL‐associated fusion proteins PML–RAR and PLZF‐RAR directly inhibit p53, allowing leukemic blasts to evade p53‐dependent cancer surveillance pathways. PML–RAR causes deacetylation and degradation of p53, resulting in repression of p53 transcriptional activity, and protection from p53‐dependent responses to genotoxic stress. These phenomena are dependent on the expression of wild‐type PML, acting as a bridge between p53 and PML–RAR. Recruitment of histone deacetylase (HDAC) to p53 and inhibition of p53 activity were abrogated by conditions that either inactivate HDACs or trigger HDAC release from the fusion protein, implicating recruitment of HDAC by PML–RAR as the mechanism underlying p53 inhibition.


Journal of Veterinary Diagnostic Investigation | 2001

Histological and immunohistochemical detection of different Helicobacter species in the gastric mucosa of cats

Eugenio Scanziani; Kenneth W. Simpson; Silvia Monestiroli; Sabina Soldati; Dalit Strauss-Ayali; Fabio Del Piero

Detailed histopathological evaluation of the gastric mucosa of Helicobacter-infected cats is complicated by the difficulty of recognizing Helicobacter organisms on hematoxylin and eosin (HE)-stained sections and the ability of multiple Helicobacter species to infect cats. In this study, the presence and localization of different species of Helicobacter in the stomachs of cats was investigated using silver staining and immuno-histochemistry. Five groups containing 5 cats each were established (group 1: urease negative and Helicobacter free; groups 2, 3, 4, and 5: urease positive and infected with Helicobacter heilmannii, unclassified Helicobacter spp., Helicobacter felis, and Helicobacter pylori, respectively). Gastric samples were evaluated by HE and silver staining and by immunohistochemistry with 3 different anti-Helicobacter primary antibodies. Helicobacter were detected by Steiner stain in all infected cats at the mucosal surface, in the lumen of gastric glands, and in the cytoplasm of parietal cells. In silver-stained sections, H. pylori was easily differentiated from H. felis, H. heilmannii, and unclassified Helicobacter spp., which were larger and more tightly coiled. No organisms were seen in uninfected cats. Helicobacter antigen paralleled the distribution of organisms observed in Steiner-stained sections for 2 of the 3 primary antibodies tested. The antisera were not able to discriminate between the different Helicobacter species examined. A small amount of Helicobacter antigen was present in the lamina propria of 3 H. pylori-, 3 H. felis-, and 1 H. heilmannii-infected cat. Minimal mononuclear inflammation was present in uninfected cats and in those infected with unclassified Helicobacter spp. and H. heilmannii cats. In H. felis-infected cats, lymphoid follicular hyperplasia with mild pangastric mononuclear inflammation and eosinophilic infiltrates were present. The H. pylori-infected cats had severe lymphoid follicular hyperplasia and mild to moderate mononuclear inflammation accompanied by the presence of neutrophils and eosinophils. These findings indicate that Steiner staining and immunohistochemistry are useful for detecting Helicobacter infections, particularly when different Helicobacter species can be present. Monoclonal antibodies specific for the different Helicobacter species could be important diagnostic aids. There appear to be differences in the severity of gastritis in cats infected with different Helicobacter species.


The Prostate | 2001

Activation of the orphan nuclear receptor RORα induces growth arrest in androgen‐independent DU 145 prostate cancer cells

Roberta M. Moretti; Marina Montagnani Marelli; Marcella Motta; Donatella Polizzi; Silvia Monestiroli; Graziella Pratesi; Patrizia Limonta

RORα is a transcription factor which belongs to the family of orphan nuclear receptors. The regulatory functions of this receptor are still poorly understood. However, response elements for RORα are present on the promoter of cell cycle‐related genes suggesting that it might be involved in the control of cell proliferation. In this study, we investigated the expression and the possible function of RORα in a human androgen‐independent prostate cancer cell line (DU 145). The thiazolidinedione‐derivative CGP 52608 has been utilized as the specific ligand and activator of RORα.


Cancer Research | 2003

Maximum Tolerable Dose and Low-Dose Metronomic Chemotherapy Have Opposite Effects on the Mobilization and Viability of Circulating Endothelial Progenitor Cells

Francesco Bertolini; Saki Paul; Patrizia Mancuso; Silvia Monestiroli; Alberto Gobbi; Yuval Shaked; Robert S. Kerbel


Cancer Research | 2002

CXCR4 Neutralization, a Novel Therapeutic Approach for Non-Hodgkin’s Lymphoma

Francesco Bertolini; Chiara Dell'agnola; Patrizia Mancuso; Cristina Rabascio; Alessandra Burlini; Silvia Monestiroli; Alberto Gobbi; Giancarlo Pruneri; Giovanni Martinelli


Cancer Research | 2001

Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma

Silvia Monestiroli; Patrizia Mancuso; Alessandra Burlini; Giancarlo Pruneri; Chiara Dell'agnola; Alberto Gobbi; Giovanni Martinelli; Francesco Bertolini


Clinical Cancer Research | 2003

Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors

Manuela Capillo; Patrizia Mancuso; Alberto Gobbi; Silvia Monestiroli; Giancarlo Pruneri; Chiara Dell'agnola; Giovanni Martinelli; Leonard D. Shultz; Francesco Bertolini


Blood | 2002

PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors

Saverio Minucci; Silvia Monestiroli; Sabrina Giavara; Simona Ronzoni; Francesco Marchesi; Alessandra Insinga; Daniela Diverio; Patrizia Gasparini; Manuela Capillo; Emanuela Colombo; Cristian Matteucci; Francesco Contegno; Francesco Lo-Coco; Eugenio Scanziani; Alberto Gobbi; Pier Giuseppe Pelicci

Collaboration


Dive into the Silvia Monestiroli's collaboration.

Top Co-Authors

Avatar

Alberto Gobbi

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Francesco Bertolini

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Pier Giuseppe Pelicci

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Saverio Minucci

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Simona Ronzoni

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Alessandra Insinga

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar

Chiara Dell'agnola

European Institute of Oncology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Manuela Capillo

European Institute of Oncology

View shared research outputs
Researchain Logo
Decentralizing Knowledge